From gene editing advances to new financing models, the scientific, business, and leadership shifts shaping tomorrow’s healthcare are imminent. Audrey Greenberg, CEO, AG Capital Advisors, discusses the future of biopharma, how precision medicine can scale from niche to population-level impact, why multi-omics and AI are reshaping prediction and prevention, and what it will take to extend equitable healthspan.
Precision medicine has been an underdelivered promise for some time. What will it take to deliver precision at scale?
Precision medicine has often meant therapies for a single patient, which are powerful but limited in reach. The problem is not the science but the infrastructure. Too much of biopharma still relies on bespoke processes. The way forward is automation, AI-driven quality, and manufacturing platforms that make customization possible at scale. That is how precision medicine becomes population medicine.
How do omics factor into this shift?
Genomics was the start, but the future is multi-omics. Proteomics, metabolomics, epigenomics, and microbiomics together give a dynamic view of health instead of a snapshot. For biopharma, this means therapies will increasingly target networks rather than single mutations. Companies that master integration of these data sources will unlock new categories of medicine.
Do you foresee a world where disease is predicted before it starts?
Yes. The combination of omics, imaging, and digital biomarkers gives us predictive power we have never had before. We can already see patterns that point to cardiovascular risk, neurodegeneration, or cancer years before symptoms appear. The science is here, but the business model is not. Payers are set up to treat illness, not prevent it. Shifting from reactive to preventive care will be one of the defining challenges of the next decade.
What can patients do at the personal level to augment this shift?
Wearables. They have evolved far beyond fitness trackers. Continuous glucose monitors, cardiac patches, and implantables now generate real-time data – but that’s where the challenge is. Physicians cannot manage an endless stream of information. AI is critical to filter and highlight what matters. Remote care will not replace in-person medicine, but it will extend the reach of clinicians into daily life in ways we have never seen before.
We can’t mention precision medicine without mentioning CRISPR and gene editing. What’s next for this technology?
CRISPR was only the beginning. Base editing, prime editing, and epigenetic reprogramming are expanding the possibilities. We are moving from fixing typos in DNA to rewriting entire sections. The potential is extraordinary, but it requires humility. Off-target effects, ethical considerations, and regulation all need to be addressed. Still, the ability to reduce susceptibility or slow biological aging is now within reach.
How does this intersect with cell and gene therapy?
Cell and gene therapies are the most direct expression of regenerative medicine, but commercialization has been slow. Manufacturing costs are high, supply chains are fragile, and reimbursement models are outdated. We must solve the issues of cost, scale, and access.
Funding feels tight just as the science is accelerating. How do you see the financial landscape?
The old model of raising large sums and rushing to initial public offering (IPO) is gone. The public markets are closed and venture investors are cautious. Other sources are filling the gap. Family offices are investing with long time horizons. Corporates are active and bring strategic value beyond capital. Sovereign wealth funds in Asia and the Middle East are engaged, and non-dilutive sources such as ARPA-H and Horizon Europe are becoming critical. The future is efficient use of capital, staged growth, and creative financing.
What are your thoughts on billionaire-backed longevity projects?
Longevity is not about vanity projects or luxury products. It is about extending healthy years through regenerative medicine, senolytics, and biomarker discovery powered by AI. The convergence of omics, prediction, and advanced therapies points toward longer healthspans. The challenge is access. If longevity is only for the wealthy, the field will have failed. If we can scale it, longevity becomes the future of healthcare.
What kind of industrial leadership will this new era require?
Leaders need to understand the full picture. They must integrate biology, technology, capital, and policy while keeping access and equity in focus. They need to build diverse teams that combine science, engineering, AI, and ethics. They must also be able to explain complex science in plain language to patients, regulators, and investors. The future of biopharma will be shaped not only by the therapies we create but by the leaders who ensure those therapies reach the people who need them.
If you had to sum up what is next for biopharma in one line, what would it be?
The future is not only about treating disease, but about predicting and preventing it. Adding years to your life and life to your years.